Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer

Breast Cancer Research and Treatment

Volumn 144, Issue 2, 2014, Pages 405-416

  Boudreau, Denise M ^a,b   Yu, Onchee ^a   Chubak, Jessica ^a   Wirtz, Heidi S ^b   Bowles, Erin J Aiello ^a   Fujii, Monica ^a   Buist, Diana S M ^a  

^a GROUP HEALTH RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antihypertensive medication; Breast cancer; Cardiovascular disease; Recurrence; Statins

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CARDIOVASCULAR AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; COMORBIDITY; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SECOND BREAST CANCER EVENT; SENSITIVITY ANALYSIS; TREATMENT DURATION; ADOLESCENT; AGED; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; EPIDEMIOLOGY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PATHOLOGY; PROGNOSIS; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RETROSPECTIVE STUDIES; WASHINGTON; YOUNG ADULT;

EID: 84896546533     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2870-5     Document Type: Article

References (69)

1. SEER Cancer Statistics Review, 1975-2009. http://seer.cancer.gov/csr/ 1975-2009-pops09/
2. Newman L (2001) IOM Report sets policy priorities for improving breast cancer screening. J Natl Cancer Inst 93(8):574-575
3. Ritchie CS, Kvale E, Fisch MJ (2011) Multimorbidity: an issue of growing importance for oncologists. J Oncol Pract 7(6):371-374
4. Boudreau DM, Yu O, Johnson J (2010) Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 9(4):603-621
5. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM (2005) Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23(34):8606-8612 (Pubitemid 46211502)
6. Undela K, Srikanth V, Bansal D (2012) Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat 135(1):261-269
7. Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, Tester W (2011) Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest 29(9):585-593
8. Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sorensen HT, Lash TL (2011) Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 103(19):1461-1468
9. Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B (2008) Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 109(3):573-579 (Pubitemid 351698864)
10. Grossman E, Messerli FH, Goldbourt U (2002) Carcinogenicity of antihypertensive therapy. Curr Hypertens Rep 4(3):195-201
11. Felmeden DC, Lip GY (2001) Antihypertensive therapy and cancer risk. Drug Saf 24(10):727-739 (Pubitemid 32848352)
12. Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, Entschladen F (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7):628-638
13. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K (2011) Beta blockers and breast cancer mortality: a populationbased study. J Clin Oncol 29(19):2635-2644
14. Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW (2011) Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 129(2):549-556
15. Nickels S, Vrieling A, Seibold P, Heinz J, Obi N, Flesch-Janys D, Chang-Claude J (2013) Mortality and recurrence risk in relation to the use of lipid-lowering drugs in a prospective breast cancer patient cohort. PLoS ONE 8(9):e75088
16. Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-Macgregor M (2013) Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J Cancer 4(7):549-556
17. Sorensen GV, Ganz PA, Cole SW, Pedersen LA, Sorensen HT, Cronin-Fenton DP, Garne JP, Christiansen PM, Lash TL, Ahern TP (2013) Use of beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin ii receptor blockers, and risk of breast cancer recurrence: a danish nationwide prospective cohort study. J Clin Oncol 31(18):2265-2272
18. McDougall JA, Malone KE, Daling JR, Cushing-Haugen KL, Porter PL, Li CI (2013) Long-term statin use and risk of ductal and lobular breast cancer among women 55-74 years of age. Cancer Epidemiol Biomarkers Prev 22(9):1529-1537
19. Li CI, Daling JR, Tang MT, Haugen KL, Porter PL, Malone KE (2013) Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Int Med 173(17): 1629-1637
20. Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16(4):508-519 (Pubitemid 34460459)
21. Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9(1):10-19 (Pubitemid 36109711)
22. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5(12):930-942 (Pubitemid 41766782)
23. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, Soria J, Soria C (2001) Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22(8):1139-1148 (Pubitemid 32737327)
24. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Nakamura H (2001) Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res 61(12):4885-4891 (Pubitemid 32691906)
25. Wong WW, Tan MM, Xia Z, Dimitroulakos J, Minden MD, Penn LZ (2001) Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res 7(7):2067-2075 (Pubitemid 32994846)
26. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V et al (2013) 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342(6162):1094-1098
27. Paquet JL, Baudouin-Legros M, Brunelle G, Meyer P (1990) Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 8(6):565-572 (Pubitemid 20301433)
28. Rosenthal T, Gavras I (2009) Angiotensin inhibition and malignancies: a review. J Hum Hypertens 23(10):623-635
29. Molteni A, Ward WF, Ts'ao CH, Taylor J, Small W Jr, Brizio-Molteni L, Veno PA (2003) Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Curr Pharm Des 9(9):751-761 (Pubitemid 36367596)
30. Fitzgerald PJ (2010) Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer. Clin Epidemiol 2:1-3
31. Fitzgerald PJ (2009) Is norepinephrine an etiological factor in some types of cancer? Int J Cancer 124(2):257-263
32. Drell TLt, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F (2003) Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 80(1):63-70
33. Lang K, Drell TLt, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 112(2):231-238
34. Masur K, Niggemann B, Zanker KS, Entschladen F (2001) Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 61(7):2866-2869 (Pubitemid 32691927)
35. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L et al (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70(18):7042-7052
36. Daling JR (1996) Calcium channel blockers and cancer: is an association biologically plausible? Am J Hypertens 9(7):713-714
37. Howes LG, Edwards CT (1998) Calcium antagonists and cancer. Is there really a link? Drug Saf 18(1):1-7 (Pubitemid 28040859)
38. Mason RP (1999) Effects of calcium channel blockers on cellular apoptosis: implications for carcinogenic potential. Cancer 85(10):2093-2102
39. Sarafidis PA, McFarlane SI, Bakris GL (2007) Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr DiabRep 7(3):191-199 (Pubitemid 46951916)
40. ALLHAT, Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288(23):2998-3007
41. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B (2005) Diabetes mellitus and breast cancer. Lancet Oncol 6(2):103-111 (Pubitemid 40197704)
42. BoydDB(2003) Insulin and cancer. IntegrCancer Ther 2(4):315-329
43. Wirtz HS, Buist DS, Gralow JR, Barlow WE, Gray S, Chubak J, Yu O, Bowles EJ, Fujii M, Boudreau DM (2013) Frequent antibiotic use and second breast cancer events. Cancer Epidemiol Biomarkers Prev 22(9):1588-1599
44. Calip GS, Boudreau DM, Loggers ET (2013) Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment. Breast Cancer Res Treat 138(1):225-233
45. Cancer Surveillance System. http://www.fhcrc.org/en/labs/phs/projects/ cancer-surveillance-system.html
46. Overview of the SEER Program. http://seer.cancer.gov/
47. Greene FL (2002) The American Joint Committee on Cancer: updating the strategies in cancer staging. Bulletin of the American College of Surgeons 87(7):13-15
48. Buist DS, Ichikawa L, Prout MN, Yood MU, Field TS, Owusu C, Geiger AM, Quinn VP, Wei F, Silliman RA (2007) Receipt of appropriate primary breast cancer therapy and adjuvant therapy are not associated with obesity in older women with access to health care. J Clin Oncol 25(23):3428-3436 (Pubitemid 47310879)
49. Enger SM, Thwin SS, Buist DS, Field T, Frost F, Geiger AM, Lash TL, Prout M, Yood MU, Wei F et al (2006) Breast cancer treatment of older women in integrated health care settings. J Clin Oncol 24(27):4377-4383 (Pubitemid 46630974)
50. Geiger AM, Thwin SS, Lash TL, Buist DS, Prout MN, Wei F, Field TS, Ulcickas Yood M, Frost FJ, Enger SM et al (2007) Recurrences and second primary breast cancers in older women with initial early-stage disease. Cancer 109(5):966-974 (Pubitemid 46333538)
51. Group Health: Breast Cancer Surveillance. http://www.group healthresearch.org/surveillanceproject/screening/history.html
52. Saunders KW, Davis RL, Stergachis A (2005) Group Health Cooperative. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, West Sussex, pp 223-239
53. Boudreau DM, Doescher MP, Jackson JE, Fishman PA, Saver BG (2004) Impact of healthcare delivery system on where HMO-enrolled seniors purchase medications. Ann Pharmacother 38(7-8):1317-1318 (Pubitemid 38802185)
54. Buist DS, LaCroix AZ, Brenneman SK, Abbott T (2004) A population-based osteoporosis screening program: who does not participate, and what are the consequences? J Am Geriatr Soc 52(7):1130-1137 (Pubitemid 38869072)
55. Death Data. http://www.doh.wa.gov/ehsphl/CHS/chs-data/death/deatmain.htm
56. Thwin SS, Clough-Gorr KM, McCarty MC, Lash TL, Alford SH, Buist DS, Enger SM, Field TS, Frost F, Wei F et al (2007) Automated inter-rater reliability assessment and electronic data collection in a multi-center breast cancer study. BMC Med Res Methodol 7:23
57. McKenney JM (2003) Pharmacologic characteristics of statins. Clin Cardiol 26(4 Suppl 3):III32-III38
58. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW et al (1995) The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274(8):620-625
59. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD et al (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25(15):2127-2132 (Pubitemid 46972801)
60. Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C (2010) Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care 48(6 Suppl):S96-S105
61. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613-619
62. Newton KM, Wagner EH, Ramsey SD, McCulloch D, Evans R, Sandhu N, Davis C (1999) The use of automated data to identify complications and comorbidities of diabetes: a validation study. J Clin Epidemiol 52(3):199-207 (Pubitemid 29148431)
63. Boudreau DM, Malone DC, Raebel MA, Fishman PA, Nichols GA, Feldstein AC, Boscoe AN, Ben-Joseph RH, Magid DJ, Okamoto LJ (2009) Health care utilization and costs by metabolic syndrome risk factors. Metab Syndr Relat Disord 7(4):305-314
64. Malone DC, Boudreau DM, Nichols GA, Raebel MA, Fishman PA, Feldstein AC, Ben-Joseph RH, Okamoto LJ, Boscoe AN, Magid DJ (2009) Association of cardiometabolic risk factors and prevalent cardiovascular events. Metab Syndr Relat Disord 7(6):585-593
65. U.S. Census Bureau (2011) Statistical abstract of the United States: 2012, 131st edn. Washington, DC
66. HMO Research Network. http://hmoresearchnetwork.org
67. Holmes MD, Hankinson SE, Feskanich D, Chen WY (2013) Beta blockers and angiotensin-converting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use. Breast Cancer Res Treat 139(2):507-513
68. George AJ, Thomas WG, Hannan RD (2010) The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 10(11):745-759
69. Phipps AI, Ichikawa L, Bowles EJ, Carney PA, Kerlikowske K, Miglioretti DL, Buist DS (2010) Defining menopausal status in epidemiologic studies: a comparison of multiple approaches and their effects on breast cancer rates. Maturitas 67(1):60-66